Background New drugs and new evidence concerning the use of established treatments
have become available since the publication of the first European League Against …

IL-1 is a master cytokine of local and systemic inflammation. With the availability of specific
IL-1 targeting therapies, a broadening list of diseases has revealed the pathologic role of IL …

Gout is the most common cause of inflammatory arthritis worldwide. In UK general practice,
the overall prevalence has increased from 1.4% in 1999 to 2.49% in 2012 [1], despite the …

Abstract Interleukin (IL)-1, first described∼ 35 years ago as a secreted product of monocytes
and neutrophils, refers to IL-1α and IL-1β, two key cytokines in the activation of innate …

Three contradictory clinical presentations of gout have puzzled clinicians and basic
scientists for some time: first, the crescendo of sterile inflammation in acute gouty arthritis; …

This review article summarizes the relevant English literature on gout from 2010 through
April 2017. It emphasizes that the current epidemiology of gout indicates a rising prevalence …

Although deposition of uric acid (UA) crystals is known as the cause of gout, it is unclear
whether UA plays a role in other inflammatory diseases. We here have shown that UA is …

Background The present review is part of the ESCMID Study Group for Infections in
Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and …

Background Activation of the NLRP3 inflammasome in gout amplifies the inflammatory
response and mediates further damage. In the current study, we assessed the therapeutic …

Objectives To evaluate the efficacy and safety of anakinra in treating acute gout flares in a
randomized, double-blind, placebo-controlled, active comparator, non-inferiority (NI) trial …